Morphometric profiling of lung cancers-its association with clinicopathologic, biologic, and molecular genetic features

American Journal of Surgical Pathology

Volumn 34, Issue 2, 2010, Pages 243-255

  Okudela, Koji ^a   Woo, Tetsukan ^a   Mitsui, Hideaki ^a   Yazawa, Takuya ^a   Shimoyamada, Hiroaki ^a   Tajiri, Michihiko ^b   Ogawa, Nobuo ^b   Masuda, Munetaka ^a   Kitamura, Hitoshi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b Kanagawa Prefectural Cardiovascular and Respiratory Center Hospital   (Japan)

Author keywords

Lung cancer; Morphometric profiling; Subtyping

Indexed keywords

DNA; TUMOR MARKER;

ARTICLE; CANCER STAGING; CELL NUCLEUS; CLASSIFICATION; CYTOPLASM; ENZYME IMMUNOASSAY; FEMALE; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; NUCLEOLUS; NUCLEOTIDE SEQUENCE; PATHOLOGY; SMALL CELL CARCINOMA; TUMOR RECURRENCE;

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CELL NUCLEOLUS; CELL NUCLEUS; CYTOPLASM; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 75649143285     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181c79a6f     Document Type: Article

References (25)

1. Asamura H, Goya T, Koshiishi Y, et al. A Japanese lung cancer registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008;3:46-52.
2. Bertheau P, Cazals-Hatem D, Meignin V, et al. Variability of immu-nohistochemical reactivity on stored paraffin slides. J Clin Pathol. 1998;51:370-374.
3. DiVito KA, Charette LA, Rimm DL, et al. Long-term preservation of antigenicity on tissue microarrays. Lab Invest. 2004;84:1071-1078.
4. Gazdar AF, Shigematsu H, Herz J, et al. Mutation and addiction to EGFR: The Achilles "heal" of lung cancer? Trends Mol Med. 2004;10:481-486.
5. Hayashi H, Miyamoto H, Ito T, et al. Analysis of p21Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma. Am J Pathol. 1997; 151:461-470.
6. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet. 2000; 355:479-485.
7. Kitamura H, Kameda Y, Nakamura N, et al. Proliferative potential and p53 overexpression in precursor and early stage lesions of bronchioloalveolar lung carcinoma. Am J Pathol. 1995;146:876-887.
8. Kitamura H, Kameda Y, Nakamura N, et al. Atypical adenomatous hyperplasia and bronchoalveolar lung carcinoma. Analysis by morphometry and the expressions of p53 and carcinoembryonic antigen. Am J Surg Pathol. 1996;20:553-562.
9. Kitamura H, Kameda Y, Ito T, et al. Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. Am J Clin Pathol. 2000;113:610-620.
10. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64:8919-8923.
11. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;150:2129-2139.
12. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710-1717.
13. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcino-ma of the lung. Histologic characteristics and prognosis. Cancer. 1995;75:2844-2852.
14. Okudela K, Hayashi H, Ito T, et al. K-ras gene mutation enhances motility of immortalized airway cells and lung adeno-carcinoma cells via Akt activation: possible contribution to non-invasive expansion of lung adenocarcinoma. Am J Pathol. 2004;164: 91-100.
15. Okudela K, Woo T, Yazawa T, et al. Significant association between EGFR-mutated lung adenocarcinoma and past illness from gastric cancer or uterine myoma: its implication in carcinogenesis. Lung Cancer. 2009;66:287-291.
16. Okudela K, Yazawa T, Woo T, et al. Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis. Am J Pathol. 2009;175:867-881.
17. Ou SH, Zell JA, Ziogas A, et al. Prognostic factors for survival of stage I non-small cell lung cancer patients: a population-based analysis of 19,702 stage I patients in the California cancer registry from 1989 to 2003. Cancer. 2007;110:1532-1541.
18. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379-392.
19. Suzuki K, Yokose T, Yoshida J, et al. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg. 2000;69:893-897.
20. Suzuki M, Shigematsu H, Iizasa T, et al. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of non-small cell lung cancer. Cancer. 2006;106:2200-2207.
21. Travis WD, Brambilla E, Muller-Hermelink HK, et al. World Health Organization Classification of Tumors. Pathology and Genetics of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.
22. Ward R, Hawkins N, O'Grady R, et al. Restriction Endonuclease-Mediated Selective Polymerase Chain Reaction. Am J Pathol. 1998; 153:373-379.
23. Woo T, Okudela K, Yazawa T, et al. Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. Lung Cancer. 2009;65:355-362.
24. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at mayo clinic from 1997 to 2003. Chest. 2005;128:452-462.
25. Yokose T, Suzuki K, Nagai K, et al. Favorable and unfavorable morphological prognostic factors in peripheral adenocarci-noma of the lung 3cm or less in diameter. Lung Cancer. 2000;29: 179-188.